Dr. Javid Moslehi is a cardiologist who specializes in the cardiovascular health of cancer patients, cancer survivors and patients with immunological or metabolic problems that affect cardiovascular health. He serves as chief of UCSF's cardio-oncology and immunology section. Moslehi's research focuses on how diseases of the cardiovascular system impact cancer patients and survivors. He is also interested in inflammatory heart conditions, such as myocarditis. Moslehi earned his medical degree from the University of Connecticut School of Medicine. He completed a residency in internal medicine at the Johns Hopkins Hospital. At Brigham and Women's Hospital, he completed a fellowship in cardiology and a postdoctoral research fellowship in oncology. His career includes directing cardio-oncology programs at the Dana-Farber Cancer Institute and Vanderbilt University Medical Center. He is the UCSF William Grossman Distinguished Professor in Cardiology.

Dr. Clara Liu Chung Ming is a Research Officer at the Heart Research Institute under Prof. Julie McMullen, specializing in bioengineering advanced 3D in vitro models to study human heart pathophysiology and cancer therapy-induced cardiotoxicity. Her work includes developing a patient-personalised platform to identify biomarkers leading to cardiotoxicity and to validate cardioprotective drugs. She has also pioneered research on the "heart attack-in-a-Petri-dish" model and investigating drug-induced cardiotoxicity using patient-derived stem cells. Clara's research extends to studying the impact of SARS-CoV-2 on human heart pathophysiology and bioengineering models of pre-eclampsia-induced heart failure using stem cells from patient’s blood. Her contributions have been recognized with multiple awards, including the FEIT HDR Women in Engineering and IT Award (2021), ASBTE Rapid Fire Presentation Award (2022), NSW Education Waratah Scholarship (2022–2024), Royal Society NSW Scholarship (2022), ASM PhD Rising Star Award (2023), Dean’s Award (2024) and Chancellor’s Award (2024) for best thesis at University of Technology Sydney.

Dr. Fradley is an attending cardiologist/electrophysiologist and Medical Director, Penn Cardio-Oncology Program and Associate Professor of Clinical Medicine at the University of Pennsylvania. He is board certified in Cardiovascular Disease as well as Internal Medicine. He then went on to complete fellowships in both Cardiology and Clinical Cardiac Electrophysiology at Massachusetts General Hospital. Dr. Fradley’s current research interests involve the treatment and prevention of cardiovascular disease in cancer patients and survivors. He has published multiple articles and also served on many committees including the Massachusetts Medical Society Committee on Medical Education and the University of South Florida LCME Faculty Affairs committee. He is also heavily involved in medical education, teaching cardiovascular pathophysiology to second year medical students, and serving as the medical director for the Harvey Simulation course. He completed his undergraduate training, with a major in Molecular Biophysics and Biochemistry, at Yale University, where he graduated cum laude with distinction in major. He received his MD degree at the Johns Hopkins School of Medicine, and then remained at Johns Hopkins, completing his residency in Internal Medicine through the Osler Medical Residency Program.Dr. Fradley is an attending cardiologist/electrophysiologist and an Assistant Professor of Medicine at the University of South Florida, Morsani College of Medicine. He serves as the director of the joint USF-Moffitt Cancer Center Cardio-Oncology Program. He is board certified in Cardiovascular Disease, clinical cardiac electrophysiology, as well as Internal Medicine.He completed his undergraduate training, with a major in Molecular Biophysics and Biochemistry, at Yale University, where he graduated cum laude with distinction in major. He received his MD degree at the Johns Hopkins School of Medicine, and then remained at Johns Hopkins, completing his residency in Internal Medicine through the Osler Medical Residency Program.He then went on to complete fellowships in both Cardiology and Clinical Cardiac Electrophysiology at Massachusetts General Hospital. Dr. Fradley’s current research interests involve the treatment and prevention of cardiovascular disease in cancer patients and survivors. He has published multiple articles and also served on many committees including the Massachusetts Medical Society Committee on Medical Education and the University of South Florida LCME Faculty Affairs committee. He is also heavily involved in medical education, teaching cardiovascular pathophysiology to second year medical students, and serving as the medical director for the Harvey Simulation course.

Dr. Melissa Reichelt is a tenured teaching and research academic in the School of Biomedical Sciences at The University of Queensland and Co-Director of the Centre for Cardiovascular Health and Research. She leads the Cardiac Disease and Therapy Group, which focuses on optimising heart function in clinically relevant models of cardiovascular disease, including chronic hypertension, myocardial ischemia, diabetes, ageing, and cancer therapy–related cardiotoxicity. Her research spans multiple levels of cardiac investigation, from single-cell populations and isolated heart function to whole-heart physiology. This work is integrated with advanced gene-editing approaches to precisely target specific cardiac cell subtypes, enabling modification of receptor expression and function in a time- and cell-specific manner. These innovative strategies for gene-based interventions hold significant potential for treating heart disease and are a major focus of her group’s ongoing research.

Dr Weeks leads the Cardiac Signalling & Metabolism Group in the Department of Anatomy & Physiology and the Baker Department of Cardiometabolic Health at the University of Melbourne. The goal of her research is to identify novel drug targets for the treatment of cardiometabolic diseases, by investigating the molecular mechanisms that contribute to cardiac growth, remodelling and dysfunction in experimental models of heart failure, diabetes and chemotherapy-induced cardiotoxicity. Dr Weeks was awarded a PhD in Biochemistry and Molecular Biology from the University of Melbourne in 2012, which she completed at the Baker Heart & Diabetes Institute under the supervision of Prof Julie McMullen. After her PhD, she was awarded a highly competitive Heart Foundation Overseas Research Scholarship to undertake postdoctoral research in Prof Metin Avkiran’s laboratory at King’s College London. Following her return to Australia, Dr Weeks was awarded an Emerging Leader Fellowship from the Baker Institute and The Shine On Foundation to support her research into the function of protein phosphatases, a family of enzymes that are having a renaissance as potential drug targets in multiple disease settings. In 2022, Dr Weeks relocated to the University of Melbourne and established the Cardiac Signalling & Metabolism Group. Her group uses in vivo mouse models, cell culture systems, molecular biology approaches and omic technologies to characterise novel signalling mechanisms that contribute to cardiac remodelling and dysfunction in cardiometabolic disease settings, including heart failure, type II diabetes and cardiotoxicity. Dr Weeks’ research is currently supported by a Heart Foundation Future Leader Fellowship and project grants from the Heart Foundation, Diabetes Australia and the Sir Edward Dunlop Medical Research Foundation.